About Novelos Therapeutics
Novelos Therapeutics is a company based in Madison (United States) founded in 1998 by Jamey Weichert.. Novelos Therapeutics has raised $53.85 million across 5 funding rounds. Novelos Therapeutics has completed 1 acquisition, including Cellectar Biosciences. Novelos Therapeutics operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others.
- Headquarter Madison, United States
- Founders Jamey Weichert
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$53.85 M (USD)
in 5 rounds
-
Latest Funding Round
$4 M (USD), Unspecified
Feb 07, 2014
-
Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Novelos Therapeutics
Novelos Therapeutics has successfully raised a total of $53.85M across 5 strategic funding rounds. The most recent funding activity was a Unspecified round of $4 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Unspecified — $4.0M
-
First Round
First Round
(25 Feb 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2014 | Amount | Unspecified - Novelos Therapeutics | Valuation |
investors |
|
| Apr, 2011 | Amount | Unspecified - Novelos Therapeutics | Valuation |
investors |
|
| Nov, 2009 | Amount | Unspecified - Novelos Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Novelos Therapeutics
Novelos Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cellectar Biosciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Phospholipid drug conjugates for cancer treatment are developed.
|
2002 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Novelos Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Novelos Therapeutics Comparisons
Competitors of Novelos Therapeutics
Novelos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| domain | founded_year | HQ Location |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic imaging agents and targeted therapeutics
|
|
| domain | founded_year | HQ Location |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Novelos Therapeutics
When was Novelos Therapeutics founded?
Novelos Therapeutics was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Where is Novelos Therapeutics located?
Novelos Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Is Novelos Therapeutics a funded company?
Novelos Therapeutics is a funded company, having raised a total of $53.85M across 5 funding rounds to date. The company's 1st funding round was a Unspecified of $9M, raised on Feb 25, 2009.
What does Novelos Therapeutics do?
Novelos Therapeutics was established in 1998 in Madison, United States, within the biotechnology sector focused on oncology. Drugs targeting cancer treatment and diagnosis are developed, including a small-molecule agent called LIGHT. Radiation is delivered selectively by this agent to cancer cells and stem cells, addressing primary tumors, metastases, and relapse mechanisms. Operations center on advancing these therapeutic and diagnostic solutions for clinical applications.
Who are the top competitors of Novelos Therapeutics?
Novelos Therapeutics's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.
How many acquisitions has Novelos Therapeutics made?
Novelos Therapeutics has made 1 acquisition, including Cellectar Biosciences.